About Rebus Biosystems
Rebus Biosystems is a Healthcare company based in Santa Clara (United States) founded in 2006 by Ron Cook and Josh Ryu. An imaging system for single-cell gene analysis is developed. Rebus Biosystems has raised $20 million across 2 funding rounds from investors including HHS, Seegene Technologies and Lifecore. Its chief executive, as recorded, is Paul Sargeant. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Cell Biology. Its competitors include 10X Genomics, Mission Bio and Cellares; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 2006 and based in Santa Clara, United States, operations focus on biotechnology and spatial omics. Patented Synthetic Aperture Optics technology is utilized for analyzing multiple gene expressions in single cells, enabling subcellular resolution imaging of full tissue sections via laser beams. The Rebus Esper platform is integrated with advancements in imaging, fluidics, chemistry, and bioinformatics to provide spatial omics data.
- Headquarters Santa Clara, United States
- Founders Ron Cook, Josh Ryu
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website rebusbio.com
- Social LinkedIn X
- Total Equity Funding$20M (USD)
in 2 rounds
- Latest Funding Round$20M (USD), Series B
Nov 2020
- InvestorsHHS
& 8 more
Funding Insights of Rebus Biosystems
Rebus Biosystems has successfully raised a total of $20M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $20M
- Total Rounds 2
- Last Round Series B — $20M
- First Round $2.24M
(Sep 2009)
- Investors Count 9
All 2 funding rounds of Rebus Biosystems with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2020 | $20M | Series B | – | Illumina Ventures | |
| Sep 2009 | $2.24M | Grant | – | – |
9 investors in total: 9 institutional.
Investors in Rebus Biosystems
Rebus Biosystems has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Seegene Technologies and Lifecore.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Health tech startups are invested in by Illumina Ventures. | illuminaventures.com | Foster City, United States | ||
Early-stage startups are funded by Seoul-based Ncore Ventures. | ncorevc.com | Seoul, South Korea | ||
| ctkinvest.com | ||||
Hyaluronan-based products for biomedical applications are developed. | 1965 | lifecore.com | Chaska, United States | |
Provides X-ray imaging solutions for the dental and medical industries. | 2004 | raymedical.com | Hwaseong, South Korea | |
LabGenomics is engaged in molecular diagnostics and personalized healthcare solutions. | labgenomics.co.kr | Seongnam, South Korea | ||
An investment management firm handling diversified funds and portfolios. | 2008 | timefolio.co.kr | Seoul, South Korea | |
Developer of molecular diagnostic kits to detect infectious and genetic diseases | 2000 | seegene.com | Seoul, South Korea | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Rebus Biosystems
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Rebus Biosystems
4 people are tracked at Rebus Biosystems (4 in leadership).
| Name | Role | Group |
|---|---|---|
Ron Cook | Co-Founder | Leadership |
Josh Ryu | Co-Founder | Leadership |
Paul Sargeant | CEO | Leadership |
Tom Willis | Interim Chief Executive Officer | Leadership |
Complete people profiles for Rebus Biosystems
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Rebus Biosystems
3 dated milestones of Rebus Biosystems across 14 years, from founding to its latest funding, stage changes and deals.
- Founded Rebus Biosystems is founded.
- Funding First funding round of $2.2M.
- Funding Latest funding round, Series B, of $20.0M.
Competitors of Rebus Biosystems
Rebus Biosystems has 3 listed competitors in our database, 3 of them funded. They include 10X Genomics, Mission Bio and Cellares.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| 10xgenomics.com | 2012 | Pleasanton, United States | $199.9M | 961 | Instrument systems for genomic research and sequencing libraries are developed. | |
| missionbio.com | 2014 | San Francisco, United States | $110M | 109 | Single-cell multi-omics platform is provided for genotypic and phenotypic analysis. | |
| cellares.com | 2019 | San Francisco, United States | $355M | Medical devices for cell-based therapy manufacturing are produced. |
Detailed competitors of Rebus Biosystems
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Rebus Biosystems (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Rebus Biosystems
Complete news archive for Rebus Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rebus Biosystems
Rebus Biosystems was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Rebus Biosystems is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Paul Sargeant is the CEO of Rebus Biosystems, as recorded in our data.
Rebus Biosystems is a funded company, having raised a total of $20M across 2 funding rounds to date. The company's 1st funding round was a Grant of $2.24M, raised on Sep 2009.
Founded in 2006 and based in Santa Clara, United States, operations focus on biotechnology and spatial omics. Patented Synthetic Aperture Optics technology is utilized for analyzing multiple gene expressions in single cells, enabling subcellular resolution imaging of full tissue sections via laser beams. The Rebus Esper platform is integrated with advancements in imaging, fluidics, chemistry, and bioinformatics to provide spatial omics data.
Rebus Biosystems's top competitors include 10X Genomics, Mission Bio and Cellares.
Rebus Biosystems has 9 investors. Key investors include HHS, Seegene Technologies, Lifecore, Illumina Ventures, and Ncore Ventures.